九州大学 研究者情報
論文一覧
帶刀 英樹(たてわきひでき) データ更新日:2019.06.05

講師 /  医学研究院 附属心臓血管研究施設


原著論文
1. Yoshiyuki Yamashita, Hideki Tatewaki, TakashiMatsumoto, Akira Shiose, Axillo-iliac artery bypass for recurrent aortic coarctation
to reduce cardiac afterload, Interactive CardioVascular and Thoracic Surgery (2018) 1–3, 10.1093/icvts/ivy115, 2018.07.
2. Kensaku Matsuda, Hideki Tatewaki, Yusaku Nagatomo, Yuichiro Hirata, Hazumu Nagata, Kazuhiro Hinokiyama, Shouichi Ohga, Akira Shiose, Two Cases of Staged Repair of Anomalous Origin of Right Pulmonary Artery
from the Ascending Aorta, Pediatric Cardiology and Cardiac Surgery 34(1): 46‒51 (2018), 2018.02, Anomalous origin of the right pulmonary artery from the ascending aorta (AORPA) is a rare congenital cardiac
malformation. Clinical manifestations usually appear in infants or, more rarely, in newborns and include
respiratory distress or congestive heart failure due to increased pulmonary resistance. Primary total correction
of AORPA reportedly can result in excellent survival with a low incidence of reintervention. We report here two
cases of staged repair of AORPA. Case 1 involved a 25-day-old girl who had a complicating respiratory syncytial
(RS) virus infection. RS virus infection in children with congenital heart disease is associated with high
mortality and morbidity, and cardiac surgery performed with cardiopulmonary bypass during symptomatic RS
virus infection is associated with a high risk of postoperative complications, especially postoperative pulmonary
hypertension. Therefore, we decided that the initial palliation should consist of right pulmonary artery banding,
and total correction was achieved 2 months later. Case 2 involved an almost 2-month-old girl who initially
underwent right pulmonary artery banding due to severe pulmonary hypertension, and total correction was
achieved 13 days later. Both patients were discharged in good condition without any clinical symptoms. Thus,
right pulmonary artery banding appears to be a good surgical option for patients with AORPA and complicated
codition..
3. Hideki Tatewaki, Egashira kensuke, Satoshi Kimura, Takahiro Nishida, Shigeki Morita, Ryuji Tominaga, Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein neointimal formation, J Vasc Surg 45:1236-1243, 2007, 45, 1236-1243, 2007.06.
4. Hideki Tatewaki, Toshihide Nakano, Hideaki Kado, Kazuhiro Hinokiyama, Daisuke Machida, Norihiko Ebuoka, Hisataka Yasui, The Yasui operation for patients with adequate-sized ventricles and ventricular septal defect associated with obstructions of the aortic arch and left ventricular outflow tract., 45(5):e166-e172, 2014, 2014.05.
5. Takahiro Nishida, Hiromichi Sonoda, Yasuhisa Oishi, Hideki Tatewaki, Yoshihisa Tanoue, Yuichi Shiokawa, Ryuji Tominaga, Long-term results of aortic valve replacement with mechanical prosthesis or carpentier-edwards perimount bioptosthesis in Japanese patients according to age, Circulation J 78(11):2688-2695, 2014, 2014.10.
6. Takahiro Nishida, Hiromichi Sonoda, Yasuhisa Oishi, Yoshihisa Tanoue, Hideki Tatewaki, Yuichi Shiokawa, Ryuji Tominaga, Long-term comparison of three types of aortic St. Jude Medical mechanical prosthesis in Japanese patients, Circulation J 79(10):2193-2200, 2015, 2015.09.
7. Toshihide Nakano, Hideaki Kado, Hideki Tatewaki, Kazuhiro Hinokiyama, Hisataka Yasui, Oda S, Ushinohama H, Sagawa K, Nakamura M, Fusazaki N, Ishikawa S, Results of extracardiac conduit total cavopulmonary connection in 500 patients, Eur J Cardiothorac Surg, 48(6):825-832, 2015, 2015.12.
8. Hideki Tatewaki, Hiroko Tsuda, Taisuke Kanaji, Kazunari Yokoyama, Naotaka Hamasaki, Characterization of the human protein S gene promoter
A possible role of transcription factors Sp1 and HNF3 in liver, Thrombosis and Haemostasis, 90, 6, 1029-1039, 2003.12, Protein S is a vitamin-K-dependent plasma glycoprotein that serves as a cofactor for activated protein C in the protein C anticoagulation pathway, which regulates blood coagulation by inactivating factors Va and VIIIa. Mechanisms regulating the expression of the protein S gene remain unknown to date. The aim of this study was to characterize the cis-acting DNA elements of the human protein S gene in liver. We found that liver cell lines (HepG2 and PLC) transcribed the human protein S gene to mRNA, whereas non-liver cell lines (HEK293 and HeLa cells) either transcribed the gene weakly or not at all. Isolation and analysis of tissue-specific gene expression in HepG2 and HeLa cells of the 5′-flanking region from -6183 to +294 of the protein S gene indicated that the consensus binding motifs to HNF3 and Sp1 or MAZ transcription factors in the flanking region are essential for protein S gene expression. Exogenous expression of the Sp1 gene augmented the protein S-reporter gene expression in HepG2 or PLC cells but had no effect in HeLa cells. Taken together, we would conclude that transcription factors of HNF3, MAZ, and Sp1 are required for high-level expression of the protein S gene in hepatic cells, but in non-hepatic cells such as HeLa cells, an unknown factor(s) binds to the Spl region and disturbs the action of Sp1 and MAZ..
9. Noriyoshi Kajihara, Shigeki Morita, Takahiro Nishida, Hideki Tatewaki, Masataka Eto, Kensuke Egashira, Hisataka Yasui, Transfection with a dominant-negative inhibitor of monocyte chemoattractant protein-1 gene improves cardiac function after 6 hours of cold preservation, Circulation, 108, 10 SUPPL., 2003.09, Background - Monocyte chemoattractant protein-1 (MCP-1), a potent chemotactic factor for monocytes, is induced during ischemia-reperfusion. As monocytes might play an important causative role in reperfusion injury, we investigated if inhibition of monocyte activation could attenuate ischemia-reperfusion injury and thereby improve cardiac preservation. To inhibit monocyte activation, we transfected a dominant-negative inhibitor of MCP-1 (7ND) gene in an animal model. Methods and Results - We used an isolated rabbit heart preparation perfused with support-rabbit blood and transfected 7ND genes to skeletal muscle of the support rabbits (n=7) using electroporation technique; causing an elevation of serum 7ND level to 20±7 pg/mL at 5 days after transfection. Animals receiving empty plasmid served as controls (n=7). Five days after transfection, hearts from other rabbits were excised, stored in UW solution for 6hours, and perfused with blood from transfected support rabbits. The 7ND group showed better cardiac output (128.7±17.9 versus 81.6±19.8 mL/min; P<0.01), lower serum CK-MB levels (5.0±1.8 versus 11.1±2.9 ng/mL; P<0.01), lower serum IL-1β levels (257.2±23.2 versus 311.2±37.4pg/mL; P<0.05), and lower serum TNF-α levels (19.0±8.4 versus 35.1± 13.0pg/mL; P<0.05). The numbers of infiltrating cells in myocardium were significantly reduced in the 7ND group. Conclusions - Inhibition of MCP-1 with 7ND gene transfection reduced cytokine activation, attenuated myocardial damage, and improved cardiac function after 6 hours of preservation. These results show that MCP-1 plays an important role in ischemia-reperfusion injury..
10. Mitsutoshi Iwaasa, Hideki Tatewaki, Tetsuji Ohno, Kenshi Okubo, Naotaka Hamasaki, Dongchon Kang, Genomic cloning and promoter analysis of a mouse anion exchanger 3 (AE3) gene, DNA Sequence - Journal of DNA Sequencing and Mapping, 10.1080/1042517021000011654, 13, 5, 251-255, 2002.12, [URL], The brain and cardiac isoforms of anion exchanger 3 (AE3) are considered to use their own promoters for their expression. However, little is known as to how the alternative transcription initiation is regulated. As a first step for elucidating the regulation, we obtained a genomic gene of mouse AE3. The 19-kbp clone contains about 6 kbp of 5′ flanking region, 23 exons, and 22 introns. We have sequenced the whole region including introns and determined the intron-exon boundaries. Six amino acids are different from those deduced from the reported mouse AE3 cDNA. We measured a promoter activity of the 5′ flanking region of the exon 1 for a brain type isoform and that of the exon C1 for a cardiac type isoform. The upstream region of the exon C1 indeed showed a promoter activity in rat cardiomyoblastic H9C2 cells, rat pheochromocyotoma PC12 cells, and human HeLa cells whereas the 5′ flanking region of the exon 1 does not in HeLa cells, suggesting that the promoter for the cardiac type is rather ubiquitously active..
11. Hideki Tatewaki, Hiroko Iida, Mutsuko Nakahara, Hiroko Tsuda, Sachiko Kinoshita, Taisuke Kanaji, Nobuyuki Yoshida, Sumio Miyazaki, Naotaka Hamasaki, A novel splice acceptor site mutation which produces multiple splicing abnormalities resulting in protein S deficiency type I, Thrombosis and Haemostasis, 82, 1, 65-71, 1999.08, In an attempt to explore the molecular mechanisms for protein S deficiency, a patient with such a deficiency was examined at the DNA, RNA and protein levels. Nucleotide analyses revealed that the proband, the mother and the grandmother had a G → C substitution in the invariant AG dinucleotide at the splicing acceptor site of intron A/exon 2. This patient was heterozygous for this substitution and the mutant allele was inherited from the proband's mother and grandmother. Reverse transcription-polymerase chain reaction analysis demonstrated several kinds of splicing abnormalities such as exon skipping and cryptic splicing, in addition to correct splicing. Semiquantitation of mRNA for the protein S gene revealed that the amount of the proband's mRNA was reduced to 60% of normal. Thus, this mutation impaired the normal processing of mRNA for the protein S gene, resulting in the subject's severe protein S deficiency..
12. K. Matsuzaki, K. Matsui, Yoshihisa Tanoue, I. Nagano, N. Haraguchi, Hideki Tatewaki, Antifibrinolytic therapy with tranexamic acid in cardiac operations, Vascular, 10.1177/096721099900700209, 7, 2, 195-199, 1999.01, [URL], To demonstrate its antifibrinolytic effects and establish an effective regimen of tranexamic acid for hemostasis, the authors measured α2-plasmin inhibitor—plasmin complexes, thrombin—antithrombin III complexes and postoperative blood loss in three groups undergoing different regimens during cardiac operations. Forty-six patients undergoing coronary artery bypass grafting or valve replacement were enrolled in this study. They were divided into three groups of drug administration. A bolus infusion of 50 mg/kg tranexamic acid was given to 17 patients at the end of cardiopulmonary bypass (control group) and to 14 patients at the beginning of cardiopulmonary bypass (group A). In addition to the same bolus infusion at the beginning of cardiopulmonary bypass as group A, a continuous infusion of 10 mg/kg per h, starting at the time of skin incision and maintained for 6 h after cardiopulmonary bypass was given to 15 patients (group B). The marked increase in α2-plasmin inhibitor—plasmin complexes at the end of cardiopulmonary bypass in the control group was significantly reduced in group A (P < 0.01) and a further reduction was observed in group B (P < 0.001). The difference in postoperative blood loss only reached significant levels between the control group and group B (P < 0.05). Although a significant increase in thrombin—antithrombin III complexes during cardiopulmonary bypass was similarly observed in all groups, no thromboembolic events occurred in any group, nor was any difference seen in graft patency. From the tranexamic acid therapy regimens tested in this study, a continuous infusion of 10 mg/kg per h starting at the time of skin incision to 6 h after cardiopulmonary bypass, with a bolus infusion of 50 mg/kg at the beginning of cardiopulmonary bypass, proved to be the most effective..
13. K. Matsuzaki, H. Okabe, N. Kajihara, N. Haraguchi, I. Nagano, Hideki Tatewaki, K. Matsui, A prospective study on the timing of discontinuation of aspirin before coronary artery bypass grafting, General Thoracic and Cardiovascular Surgery, 45, 10, 1710-1714, 1997.12, The effects of the timing of discontinuation of aspirin before coronary artery bypass grafting (CABG) on postoperative blood loss and blood requirements were examined in 22 patients undergoing elective CABG, who were randomly assigned into two groups. In Group I (11 patients), aspirin was discontinued two days before the operation and in Group II (11 patients), aspirin was continued up to the operation. The other 40 patients, who did not take aspirin for at least seven days before the operation, served as a control Group. There were no differences in preoperative data including the platelet count and the hemoglobin concentration, nor in operative variables such as operation time, cardiopulmonary bypass duration and aortic crossclamp time among the groups. Although postoperative blood loss (six hours' loss; Group I 218 ml, Group II 183 ml and control Group 172 ml) and red blood cells transfusion requirements were not different among the groups, platelet concentrates transfusion was more frequently required in Group II (54.5%) as compared with control Group (7.5%) and Group I (9.1%). The difference between Group II and the control Group reached statistical significance (p<0.01), but there was no significant difference between Group I and control Group. This fact suggests that preoperative two days' discontinuation of aspirin works as effectively as seven days' discontinuation..
14. K. Matsuzaki, I. Nagano, Hideki Tatewaki, K. Matsui, A catheter-guided insertion of Pacifico's venous cannula, Japanese Journal of Thoracic Surgery, 49, 10, 813-814, 1996.09, Direct caval cannulation using a Pecifico's cannula has become popular in open heart surgery. However, the cannulation is often difficult especially in pediatric cases because of the right-angled, blunt and large metal tip of the catheter. To resolve this problem, we introduced a catheter-guided insertion of the cannula using an intratracheal suction catheter (IZUMO Health, Nagano, Japan) of an appropriate size as a guiding catheter. With this technique, no special skills are necessary to establish direct caval cannulation..

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。
 
 
九州大学知的財産本部「九州大学Seeds集」